In vitro analysis of new putative biomarkers for OCT2/MATE-mediated renal drug-drug interactions

被引：0
|
作者：
Picurova, J. [1 ]
Mueller, F. [1 ,2 ]
Koenig, J. [1 ]
Stopfer, P. [1 ]
Fromm, M. F. [1 ]
Gessner, A. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Numberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P075
引用
收藏
页码：S35 / S36
页数：2
相关论文
共 50 条
  • [1] N1-Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid
    Mueller, Fabian
    Hohl, Kathrin
    Keller, Sascha
    Schmidt-Gerets, Sven
    Deutsch, Birgit
    Schuler-Metz, Annette
    Fromm, Martin F.
    Stopfer, Peter
    Gessner, Arne
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (05) : 1070 - 1079
  • [2] Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach
    Mathialagan, Sumathy
    Feng, Bo
    Rodrigues, A. David
    Varma, Manthena V. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 855 - 859
  • [3] Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1/2-K Transporters
    Krishnan, Srinivasan
    Ramsden, Diane
    Ferguson, Douglas
    Stahl, Simone H.
    Wang, Joanne
    McGinnity, Dermot F.
    Hariparsad, Niresh
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 562 - 572
  • [4] Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2
    Shu, Wenying
    Ma, Lei
    Hu, Xiaoye
    Zhang, Meimei
    Chen, Wensheng
    Ma, Wen
    Huang, Jianing
    Li, Jia
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 142
  • [5] Drug-drug interaction between pramipexole and cimetidine, an OCT2 inhibitor.
    Kang, Byung-Sung
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E234 - E234
  • [6] Prediction of Clinical Drug-Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)
    Kikuchi, Ryota
    Lao, Yanbin
    Bow, Daniel A. J.
    Chiou, William J.
    Andracki, Mark E.
    Carr, Robert A.
    Voorman, Richard L.
    De Morais, Sonia M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (12) : 4426 - 4432
  • [7] Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K)
    Saad, Abdulaziz Ahmed A.
    Zhang, Fan
    Mohammed, Eyad Abdulwhab H.
    Wu, Xin'an
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (04) : 382 - 393
  • [8] Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters
    Lin, Kexin
    Kong, Xiaorui
    Tao, Xufeng
    Zhai, Xiaohan
    Lv, Linlin
    Dong, Deshi
    Yang, Shilei
    Zhu, Yanna
    MOLECULES, 2023, 28 (13):
  • [9] In Vitro testing of Bilastine For Transporter Mediated Drug-Drug Interactions
    Ganza, Alvaro
    Ortega, Ignacio
    Gonzalo, Ana
    Luisa Lucero, Maria
    Jahic, Mirza
    Bednarczyk, Dallas
    Gedey, Szilvia
    Nagy, Zoltan
    Juhasz, Viktoria
    Ioja, Eniko
    DRUG METABOLISM REVIEWS, 2010, 42 : 303 - 303
  • [10] IN VITRO EVALUATION OF TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS
    Feng, Bo
    Mireles, Rouchelle
    DRUG METABOLISM REVIEWS, 2008, 40 : 154 - 154
12345